SLU-PP-332

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptor (ERR) family (ERRalpha, ERRbeta, and ERRgamma), supplied here as an oral capsule format for laboratory and professional reference use. ERRs are orphan nuclear receptors that act as transcriptional regulators of genes governing mitochondrial biogenesis, oxidative metabolism, and energy expenditure. SLU-PP-332 has drawn attention in the preclinical metabolic and exercise-physiology literature as a research tool compound, often characterized as an "exercise mimetic" candidate because of the metabolic gene-expression patterns observed in published model systems.

This material is provided strictly for research and professional use and is not approved by the FDA for therapeutic use. It is not a drug, dietary supplement, or food, and the description above summarizes general areas of scientific interest rather than any established clinical application. Individual results vary, and nothing here should be read as a statement of efficacy or safety in humans.

• Investigated in preclinical literature for its role as an ERR pan-agonist and the downstream regulation of mitochondrial biogenesis
• Studied in research models for activation of oxidative metabolism and skeletal-muscle energy-expenditure pathways
• Reported in early research as an 'exercise mimetic' tool compound for examining metabolic adaptation without physical activity
• Examined in preclinical work exploring fatty-acid oxidation and substrate-utilization signaling
• Of research interest in the broader study of metabolic and weight-related pathways at the receptor and gene-expression level

Handling reference: store the sealed oral capsule product in a cool, dry location away from direct light and excess humidity; refrigeration may be used to support long-term stability, and freezing should be avoided unless otherwise indicated by the certificate of analysis. Reconstitution with bacteriostatic water applies only to lyophilized/injectable peptide presentations and is generally not applicable to an oral capsule format; where a reconstitution-type product is being referenced, prepared solutions are typically kept refrigerated, protected from light, and used within the stability window noted on the COA. Keep out of reach of children and unauthorized persons, label clearly as a research material, and follow your facility's standard handling and documentation practices. All clinical and handling protocols are determined solely by the licensed ordering provider at their own professional discretion; this is reference information only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In published preclinical work, SLU-PP-332 is described as a direct agonist of the estrogen-related receptors (ERRalpha/beta/gamma), nuclear receptors that coordinate transcriptional programs tied to mitochondrial function and oxidative energy metabolism. By engaging these receptors, the compound is reported in research settings to upregulate genes associated with mitochondrial biogenesis and fatty-acid oxidation, producing a metabolic signature that investigators have compared to certain adaptations seen with physical exercise. This proposed mechanism is drawn from cell and animal model literature and has not been established in humans; individual results vary and the pathway description is provided for scientific reference only.